The US Food and Drug Administration has granted final approval for Israeli firm Teva Pharmaceutical Industries' Abbreviated New Drug Application for rabeprazole sodium delayed-release tablets, 20mg.
Teva's rabeprazole product is the AB-rated generic equivalent of Eisai's acid pump inhibitor Aciphex, which had annual sales of approximately $1.3 billion, based on IMS Health sales data.
As one of the first companies to file an ANDA containing a paragraph IV certification for this product, Teva says it has been awarded a 180-day period of marketing exclusivity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze